Expanded Access to Triheptanoin

Ultragenyx

Status

Conditions: Long Chain Fatty Acid Oxidation Disorders

Treatments: Drug: Triheptanoin

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03773770

UX007-EAP

Details and patient eligibility

About

Expanded access may be provided for qualified patients who have limited treatment options and are not eligible for a clinical trial.

Full description

Long Chain Fatty Acid Oxidation Disorders (LC-FAOD) and other Non-FAOD conditions, where applicable: Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies.

For full details, please visit the links provided below.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

- The participant must not be eligible for a UX007 clinical trial